In this study, susceptibility varied among European Gram-negative isolates from pediatric intra-abdominal infections. Resistance, rates of extended-spectrum β-lactamase-positive isolates, and multidrug-resistance rates were substantially higher in isolates from hospital-associated infections than in those from community-associated infections and were higher in ICUs than in general wards, which suggests that different empiric therapy strategies are needed in different settings.
INTRODUCTION
The most common type of intra-abdominal infection (IAI) is appendicitis, which occurs most frequently in children and young adults [1, 2] , yet not many studies have been published on the microbiology of pediatric IAI. Most of them were single-center studies with sample sizes generally too small to compare subsets such as hospital-associated (HA) and community-associated (CA) IAI or isolates from intensive care units (ICUs) and non-ICU wards [3] [4] [5] [6] [7] [8] [9] [10] . Some larger-scale surveillance studies of IAI isolates collected worldwide from 2008 to 2010 showed differences in antimicrobial susceptibility between adults and children [11] and between pediatric patients in ICU and non-ICU settings [12] . However, to our knowledge, no studies that used more recent data, showed region-specific results, or performed detailed subset analyses for children with IAI have been published. Our study focused on pediatric IAI in Europe to assess whether susceptibility patterns that would be useful to clinicians when selecting empiric therapy can be identified. This information is especially important for complicated IAI (ie, an IAI that extends beyond the hollow viscus of origin into a normally sterile area of the abdomen), for which appendicitis-related antimicrobial treatment needs to be initiated before microbiological culture results are available. Furthermore, nonoperative management of uncomplicated appendicitis, which has been shown to be feasible for children, requires empiric antimicrobial therapy [13, 14] . Such empiric treatment decisions can be supported with data from surveillance studies that monitor resistance trends, including the increases in extended-spectrum β-lactamases (ESBLs) that have been reported worldwide [15] . The data for this study came from the Study for Monitoring Antimicrobial Resistance Trends (SMART), which has been monitoring the epidemiology and antimicrobial susceptibility of IAI pathogens worldwide since 2002.
MATERIALS AND METHODS
Participating sites each collected up to 100 consecutive aerobic or facultative anaerobic Gram-negative pathogens from patients with IAI per year. Only 1 isolate per species per patient (the first isolate for a particular species) was allowed. Between 2011 and 2014, 1259 IAI isolates from pediatric (<18-year-old) patients were collected at 44 hospitals in 16 countries: Croatia (1 site), Czech Republic (1), France (4), Germany (5), Greece (2), Hungary (2), Italy (4), Lithuania (1), Portugal (2), Romania (2), Serbia (2), Slovenia (1), Spain (11) , Switzerland (1), Turkey (3) , and the United Kingdom (2) . Approximately four-fifths of the sites were university hospitals or other tertiary care centers, and approximately one-fifth of them were community or regional hospitals. None of the centers was a stand-alone pediatric hospital. The most common specimen sources were peritoneal fluid (35.0%), appendix (28.1%), abscess (19.9%), intestine (6.5%), and stomach (4.8%).
Isolates were identified to the species level and sent to 1 of 2 central laboratories (International Health Management Associates, Inc., Schaumburg, Illinois, or International Health Management Associates Europe Sàrl, Épalinges, Switzerland), which used identical protocols for susceptibility testing and confirmation of identification. Isolates were identified to the species level using the RapID One biochemical system (Remel, Lenexa, Kansas) in 2011 and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Bremen, Germany) in 2012-2014. Minimal inhibitory concentrations (MICs) were determined by using the Clinical and Laboratory Standards Institute broth microdilution method with customized dehydrated MicroScan panels (Beckman Coulter, Inc., West Sacramento, California) [16] . Interpretive MIC criteria followed the 2015 European Committee on Antimicrobial Susceptibility Testing guidelines [17] . For the calculation of susceptibility of all Gram-negative pathogens combined, breakpoints appropriate for each species were used, and 0% susceptible was assumed for species with no breakpoints for any given drug.
Quality control was performed on each day of testing using appropriate American Type Culture Collection control strains and following Clinical and Laboratory Standards Institute and panel manufacturer guidelines. Results were included in the analysis only when corresponding quality control results were within an acceptable range [18] . Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus mirabilis were classified as ESBL producers if there was at least an 8-fold reduction in their MIC for ceftazidime or cefotaxime tested in combination with clavulanic acid versus their MIC when tested alone [18] . Multidrug resistance (MDR) was defined as resistance to 3 or more of the tested antimicrobial drug classes (aminoglycosides, β-lactam/β-lactamase inhibitor combinations, cephems, carbapenems, and quinolones). Similar to the process followed by other SMART studies [19, 20] , regional MDR rates within Europe were calculated by assigning participating countries to 1 of 3 regions based loosely on geographic lines: West (France, Germany, Italy, Portugal, Spain, Switzerland, and United Kingdom), Central (Croatia, Czech Republic, Hungary, and Slovenia), or Southeast (Greece, Romania, Serbia, and Turkey). There were too few isolates from the Baltic region to include the isolates from Lithuania in this regional analysis. The regional rates enabled the assessment of variability of MDR rates within Europe but avoided the reporting of national estimates that were potentially unreliable because of small sample sizes and low site counts. An IAI was defined as HA or CA if cultured ≥48 or <48 hours after admission, respectively.
Differences in susceptibility and ESBL and MDR rates between isolates from HA and CA IAI, from ICUs and non-ICU wards, and from infants (aged <1 year) and older children (aged 1-17 years) were assessed with the Fisher exact test. A P value of <.05 was considered statistically significant. Confidence intervals were calculated by using the adjusted Wald method. Statistical analyses were performed with XLSTAT Version 2015.2.01 (Addinsoft, New York).
RESULTS
Of the 1259 aerobic or facultative anaerobic Gram-negative pathogens, the 4 most common species were E coli, Pseudomonas aeruginosa, K pneumoniae, and Enterobacter cloacae ( Table 1) . These were also among the 5 most common species in isolates from HA and CA IAI, from ICUs and non-ICU wards, and from both age groups; however, the relative proportions varied across subsets. In isolates from HA IAI, ICUs, and infants (aged <1 year), E coli, although still the most frequent pathogen, was found in less than 54% of infections, whereas its proportion was significantly greater in CA IAI, non-ICU wards, and older children (≥69%). In contrast, K pneumoniae and E cloacae were significantly more common in HA IAI, ICUs, and infants than in CA IAI, non-ICU wards, and older patients. The occurrence of P aeruginosa was ∼10% in all except the infants subset (in which the sample sizes were small).
Susceptibility of E coli was >90% to all study drugs except ampicillin-sulbactam and the fluoroquinolones ( Table 2 ). The differences in susceptibility between HA and CA IAI were statistically significant for all agents except amikacin and the carbapenems; isolates from HA IAI were generally less susceptible by 4 to 9 percentage points. The susceptibility of E coli isolates did not vary significantly between ICU and non-ICU isolates, although the difference for piperacillin-tazobactam approached statistical significance (P = .087). Susceptibility to cephalosporins was at least 10 percentage points lower and to amikacin and piperacillin-tazobactam approximately 6 percentage points lower in isolates from infants than in those from patients ≥1 year of age; these differences were statistically significant (P < .05) for all agents except piperacillin-tazobactam (P = .074).
P aeruginosa isolates were ≥90% susceptible to imipenem, cefepime, ceftazidime, piperacillin-tazobactam, and amikacin. No significant differences were found between HA and CA IAI isolates or in those from both age groups in this study. Susceptibility was significantly lower in ICU isolates than in non-ICU isolates for only ciprofloxacin and amikacin.
Antimicrobial activity against K pneumoniae isolates was generally low; only the carbapenems showed susceptibilities of ≥90% (in all subsets except ertapenem in non-ICU wards), and amikacin had susceptibilities of ≥80% (in all subsets except infants). Activity was especially reduced in HA IAI isolates, and there were significantly lower susceptibilities (by ≥22 percentage points) for most cephalosporins and the fluoroquinolones, with ceftazidime and ampicillin-sulbactam approaching significance (P = .070 and .078, respectively). The differences in susceptibility in isolates from ICUs and those from non-ICU wards were slightly smaller (≥16 percentage points lower in isolates from ICUs for all agents except the carbapenems and amikacin) and were statistically significant for most cephalosporins, ampicillin-sulbactam, and levofloxacin (P < .05), with cefepime approaching significance (P =.087). Susceptibility was 10 to 27 percentage points lower in isolates from infants than those from older children for all agents except carbapenems, but these differences were statistically significant for only ceftriaxone, cefotaxime, and piperacillin-tazobactam.
Overall susceptibility was also low in E cloacae isolates, and the susceptibility of none of the tested drugs except imipenem exceeded 90%. Differences in susceptibility between isolates from HA and CA IAI were dramatic (and statistically significant) for all agents except the carbapenems and β-lactam/β-lactamase inhibitor combinations; susceptibility to the cephalosporins was lower by more than 37 percentage points in isolates from HA IAI. Similar differences were found between ICU and non-ICU isolates and between isolates from both age groups in this study.
The results for K pneumoniae and E cloacae were affected by isolates from a single institution in Hungary. This site collected more than 10% (11 of 83) of the study's K pneumoniae isolates. Eight of the 11 strains were MDR and ESBL positive, and these 8 strains came from HA IAI and from ICU patients <1 year of age. The same site also submitted almost one-fifth (9 of 53) of the E cloacae isolates. Eight of the 9 isolates were MDR, and these 8 isolates were from HA IAI and ICU patients <1 year of age. However, even taking all isolates from this site out of the analysis, susceptibilities of the remaining K pneumoniae isolates were ∼13 to 25 percentage points lower in HA IAI than in CA IAI for ampicillin-sulbactam, cephalosporins, and fluoroquinolones and 11 to 24 percentage points lower in ICU isolates than in non-ICU isolates for ampicillin-sulbactam and cephalosporins (data not shown). Similarly, susceptibility of E cloacae to cephalosporins and β-lactam/β-lactamase inhibitor combinations was still 18 to 37 percentage points lower in HA IAI isolates than in The sum of HA and CA isolates is smaller than the total number of isolates because for 23 isolates no length-of-stay information was available; the sum of ICU and non-ICU ward isolates is smaller than the total because 208 isolates came from locations other than an ICU or non-ICU ward, such as an emergency department, or the patient location was not specified.
CA IAI isolates, and susceptibilities to ertapenem, all cephalosporins except cefepime, and piperacillin-tazobactam were still ≥25 percentage points lower in ICU isolates than in non-ICU isolates. The differences between age strata after exclusion of the Hungarian site were smaller, with susceptibilities of E cloacae to cephalosporins, ertapenem, and piperacillin-tazobactam lower in isolates from infants than in those from older children by 6 to 11 percentage points and susceptibilities of K pneumoniae to the carbapenems and piperacillin-tazobactam lower in isolates from infants by 6 to 10 percentage points. In contrast, susceptibility of K pneumoniae to fluoroquinolones was 11 to 20 percentage points higher in isolates from infants. Susceptibilities were also calculated for all Gram-negative pathogens combined to further aid in empiric therapy decisions. Only imipenem and amikacin demonstrated susceptibilities of >90% overall, and ertapenem, cefepime, ceftazidime, piperacillin-tazobactam, and the fluoroquinolones showed susceptibilities of ≥85%. Susceptibilities for all agents were significantly lower in isolates from HA IAI than in those from CA IAI. In isolates from HA IAI, only imipenem and amikacin exceeded 90% susceptibilities, and those of ertapenem and piperacillin-tazobactam exceeded 80%. Differences in activity in isolates from ICU and non-ICU wards were slightly smaller but still statistically significant for all agents, and differences between the age groups were generally even larger (and statistically significant for all agents). Imipenem was the only drug to exceed 90% susceptibility in ICUs and in infants. MDR rates were calculated for the top 4 species and for all Gram-negative pathogens combined and ranged from 5.1% for E coli to 30.1% for K pneumoniae (Table 3) . MDR rates were higher in isolates from HA IAI than in those from CA IAI, and these differences were statistically significant for E coli, E cloacae, and all Gram-negative pathogens combined, with the difference for K pneumoniae nearly significant (P = .061). Rates were also higher in ICU isolates than in non-ICU isolates, but the differences were significant only for E cloacae and all Gramnegative pathogens combined. Finally, MDR rates were higher in isolates from infants than in those from children ≥1 year of age, and the differences were significant for E coli, E cloacae, and all Gram-negative pathogens combined. Rates of ESBL-positive isolates showed a similar pattern, with the highest rate of 33.7% for K pneumoniae (Table 4) . ESBL-positive rates were generally higher in isolates from HA IAI, ICUs, and infants, but these differences were only statistically significant when E coli isolates from HA and CA IAI and K pneumoniae isolates from ICUs and non-ICU wards were compared.
Within Europe, MDR rates varied according to region (Figure 1 ). The lowest rate was found in the West region (5.1%), the rate in the Southeast region was more than twice as high (11.5%), and the highest rate was in the Central region (24.5%, albeit with large confidence intervals and in part because of the high rates at the Hungarian site).
DISCUSSION
Studies of the microbiology of pediatric IAI are rare. In this study, we examined microbiological characteristics of IAI in children in Europe, allowing comparison to older studies and studies including the entire age range of patients. The top 4 species were the same as those found in other studies of IAI, regardless of whether the studies were of pediatric patients from just 1 hospital (in Israel [4] and Taiwan [6] ) or whether these studies were also large-scale SMART surveillance reports (using pediatric isolates collected between 2008 and 2010 worldwide [12] , isolates from patients of all ages collected between 2008 and 2010 worldwide [11] , or 2008 isolates from European patients of all ages [21] ). In this and other pediatric studies, E coli made up a greater proportion of total isolates than in studies of isolates from adults or from patients of all ages [6, 11, 12, 21] . The predominance of E coli in our study was especially striking in the subsets of isolates from CA IAI, from non-ICU wards, and from patients ≥1 year of age, whereas the proportion of K pneumoniae isolates was high in isolates from HA IAI, ICUs, and infants. It is interesting to note that the P aeruginosa prevalence of ∼10% was not higher in isolates from HA infections or from ICUs. Badal et al. [12] reported similar findings in a 2008-2010 SMART study in which global pediatric IAI isolates from ICUs (11%) and non-ICU wards (9%) were compared, and Newman et al. [4] found a similarly high prevalence of P aeruginosa in pediatric CA IAI in a study in a pediatric surgery department (11%).
The susceptibilities of E coli were at least 6 percentage points higher and those of P aeruginosa at least 12 percentage points higher for cephalosporins, fluoroquinolones, and piperacillin-tazobactam than the percent susceptibilities reported for European IAI isolates from 2008 SMART data [21] . This finding most likely reflects the fact that the 2008 SMART study included Abbreviations: CA, community associated; ESBL, extended-spectrum β-lactamase; HA, hospital associated; IAI, intra-abdominal infection; ICU, intensive care unit. a Significant differences (P < .05, Fisher exact test) between HA and CA, between ICUs and non-ICU wards, or between age groups.
<10% pediatric isolates, thus supporting other findings in the literature that E coli isolates are generally more susceptible in the pediatric population than in adults [11] . However, this was not the case for K pneumoniae; the susceptibilities of pediatric isolates for most agents were 4 to 13 percentage points lower than those in the 2008 SMART IAI report [21] . ESBL-positive rates showed a related pattern. Although the rate for E coli in this pediatric population was lower than that in the 2008 SMART study of IAI in European patients of all ages (6.8% vs 11.6%) [21] , the rate in K pneumoniae was strikingly higher (33.7% vs 17.9%). The high resistance rates in K pneumoniae were partly because of the isolates from a single Hungarian site, but even without this site, the ESBL-positive rate would still have been higher at 26.4% (data not shown). Because ESBL-positive rates have been increasing in Europe in recent years, especially in K pneumoniae [15, 22, 23] , it is likely that it has also affected pediatric isolates. As opposed to small single-center studies, this large-scale surveillance study enabled subset analyses according to whether the infection was likely acquired in the community or in the hospital and according to the type of hospital ward and age group. The importance of stratification by such variables was reiterated recently by Bielicki et al. [24] . In our study, the susceptibilities of E coli, K pneumoniae, and E cloacae were generally lower in isolates from HA IAI than in those from CA IAI, lower in ICUs than in non-ICU wards, and lower in patients <1 year of age than in older children. Concomitantly, ESBL-positive rates were higher in isolates from HA IAI, ICUs, and infants and were likely at least in part the cause of the higher MDR rates in these settings, because ESBL-producing Enterobacteriaceae often show coresistance to other drug classes.
The finding of higher resistance in infants is contrary to recent results reported by Bielicki et al. [24] , who found higher resistance in bloodstream infection isolates from children ≥1 year of age than in those from infants. These conflicting results likely arise from the fact that the etiology of pediatric IAI varies substantially between both of these age groups. The most frequent cause of IAI in older children is appendicitis, which is typically community-associated, whereas IAI presents very differently in infants, for example as necrotizing enterocolitis (NEC) (the most common cause of IAI in neonates) [25] . Accordingly, 70% of the isolates from our sample of children ≥1 year old were of CA IAI, whereas 71% of isolates from infants were of HA IAI. Furthermore, 66% of infant isolates were from ICUs, but in older children, only 24% were ICU isolates. Both these findings can readily account for the higher resistance found in infants in our study. The high proportion of ICU isolates in the infant stratum is also consistent with our finding of high prevalences of K pneumoniae and E cloacae among IAI isolates from infants. Mollitt et al. [26] found high prevalences of Klebsiella and Enterobacter species in a study of newborns with NEC, and they suggested that this unique bacteriology probably reflects abnormal colonization in the neonatal ICU. It is unfortunate that the SMART program does not collect detailed clinical data, so the proportion of infants with NEC is unknown.
It is interesting that no significant differences in susceptibility and MDR rates in isolates from HA IAI and in those from CA IAI were found for P aeruginosa, and there were few differences between the isolates from ICUs and those from non-ICU wards. In fact, this species was surprisingly susceptible across all settings. Together with the finding that P aeruginosa isolates were not more common in HA and ICU infections, these results suggest that pediatric patients rarely picked up the usually more resistant P aeruginosa organisms found in the hospital and especially in ICUs. Instead, it seems more likely that their infections were caused by P aeruginosa from their own intestinal flora.
According to the guidelines of the Surgical Infection Society (SIS) and the Infectious Diseases Society of America (IDSA), antimicrobial therapy should be started as soon as a diagnosis of IAI is made or considered likely [27] . Therefore, therapy for IAI is usually empiric. Judging from the MDR results stratified according to region and the data of the Hungarian site, it is important to consider regional, national, or, if available, local resistance patterns when selecting empiric therapy options. In addition, our data suggest that those who make treatment decisions should take into account the type of ward, the age of the patient, and whether the infection was likely acquired in the community or the hospital. For example, against K pneumoniae isolates from HA IAI, from ICUs, and from infants, only ertapenem and imipenem exceeded 85% susceptibility; in non-ICU wards and for older children, amikacin also exceeded this threshold; and in CA IAI, all tested drug classes except β-lactam/β-lactamase inhibitor combinations were >85% active in vitro. When all Gram-negative pathogens were combined, only imipenem was found to be highly active in each setting (>90%). In addition, in isolates from CA infection, ertapenem, cefepime, ceftazidime, piperacillin-tazobactam, the fluoroquinolones, and amikacin were active in vitro against at least 88% of Gramnegative isolates. The SIS/IDSA guidelines, which include recommendations specifically for pediatric IAI, recommend all these agents or drug classes, except for fluoroquinolones, for pediatric CA IAI. In addition, the guidelines list cefotaxime and ceftriaxone; however, in this study, susceptibilities were <83% for these cephalosporins for isolates from CA IAI. According to the SIS/IDSA recommendations, empiric therapy for HA IAI should be driven by local susceptibility patterns. Multidrug regimens and broad-spectrum agents may be needed, including ceftazidime or cefepime plus metronidazole, group 2 carbapenems, piperacillin-tazobactam, aminoglycosides, and colistin. Of these agents, imipenem and amikacin had the highest activity (>90%) in vitro against pathogens from HA IAI in this study, and the cephalosporins had the lowest activity (<80%) (colistin was not tested).
The main limitation of this study is the somewhat imperfect categorization of isolates as HA or CA IAI. Our 48-hour threshold for HA infections is equivalent to the definition used by the Centers for Disease Control and Prevention for the National Healthcare Safety Network surveillance program (ie, an infection that first presents on the third calendar day after admission) [28] . However, if patients who were newly admitted to a hospital had been transferred from another healthcare facility, their infection within 48 hours could be wrongly categorized as CA. However, it is reassuring that in this study, as in other studies that used this definition, results have indicated clear patterns of lower susceptibility and higher ESBL-positive rates in HA IAI than in CA IAI [29] [30] [31] [32] . Another limitation of large-scale surveillance studies is sampling variation between sites and countries and the low number of sites per country, as illustrated by the example of a Hungarian site that affected the regional MDR rate and susceptibility estimates in ICUs and HA IAI for Europe overall. In addition, surveillance studies are affected by sites and even entire countries dropping in and out of the study over time and by sample sizes that are often too small for more detailed analyses of subsets (especially among pediatric isolates). We tried to at least partially address these issues by using 4 years of data from across Europe, which resulted in a collection of 1259 isolates from 44 sites in 16 countries. Another limitation of this study, and of most other large-scale surveillance studies, is the lack of clinical data that would allow more detailed stratified analyses of the susceptibility data. Finally, this study is also limited in its generalizability to uncomplicated IAI, especially in otherwise healthy children in community hospitals, because the majority of participating hospitals were tertiary care centers with resistance patterns that are different than those in smaller hospitals and likely have a large share of complicated IAI and/or children with comorbidities.
Although antimicrobial resistance is generally thought to be a smaller problem in pediatric patients than in adults, this study of pediatric IAI in Europe found substantial resistance, MDR, and ESBL-positive rates in isolates from HA IAI, ICUs, and infants, especially in K pneumoniae. These findings, together with knowledge of regional, national, and local resistance patterns, can aid in the selection of empiric treatment options. Future studies that also are able to correlate clinical parameters and risk factors with antimicrobial resistance patterns and patient outcomes could further improve clinical practice by helping select empiric treatment according to patient characteristics.
Notes

